Ex-hedge Funder Buys Rights to Life-Saving Drug and Raises Price from $13.50 to $750 per pill
By Tom Boggioni / rawstory.com
Sep 22, 2015

Martin Shkreli, founder and chief executive of Turing Pharmaceuticals -- Twitter

A former hedge fund manager turned pharmaceutical businessman has purchased the rights to a 62-year-old drug used for treating life-threatening parasitic infections and raised the price overnight from $13.50 per tablet to $750.

According to the New York Times, Martin Shkreli, 32, the founder and chief executive of Turing Pharmaceuticals, purchased the rights to Daraprim for $55 million on the same day that Turing announced it had raised $90 million from Shkreli and other investors in its first round of financing.

Daraprim is used for treating toxoplasmosis — an opportunistic parasitic infection that can cause serious or even life-threatening problems in babies and for people with compromised immune systems like AIDS patients and certain cancer patients — that sold for slightly over $1 a tablet several years ago.  Prices have increased as the rights to the drug have been passed from one pharmaceutical company to the next, but nothing like the almost 5,500 percent increase since Shkreli acquired it.

Worrying that the cost of treatment could devastate some patients, Dr. Judith Aberg, the chief of the division of infectious diseases at the Icahn School of Medicine at Mount Sinai asked, “What is it that they are doing differently that has led to this dramatic increase?”

According to Shkreli, Turing will use the money it earns to develop better treatments for toxoplasmosis, with fewer side effects.

“This isn’t the greedy drug company trying to gouge patients, it is us trying to stay in business,” Shkreli explained, saying that many patients use the drug for far less than a year and that the new price is similar to other drugs used for rare diseases.

Shrkeli also defended his small pharmaceutical company saying, “It really doesn’t make sense to get any criticism for this.”

This is not the first time the fledgling pharmaceutical executive has come under scrutiny.

He started the hedge fund MSMB Capital while in his 20’s and was accused of urging the FDA to not approve certain drugs made by companies whose stock he was shorting.

In 2011,  Shkreli helped form Retrophin, which also acquired old drugs and immediately raised their prices. Retrophin’s board fired Shkreli a year ago and has filed a complaint in Federal District Court, accusing him of using Retrophin as a personal fund to pay back angry investors in his hedge fund.

 As for Shrkeli’s claim that he will put the excess profits back into research, doctors say that isn’t needed in this case.

“I certainly don’t think this is one of those diseases where we have been clamoring for better therapies,” said Dr. Wendy Armstrong, professor of infectious diseases at Emory University in Atlanta.

Image: Martin Shkreli, founder and chief executive of Turing Pharmaceuticals -- Twitter

4.0 ·
2
Featured Pay Per View Films
Generation Revolution (2017)
72 min
Inhabit: A Permaculture Perspective (2015)
92 min
Fall and Winter (2013)
102 min
Trending Today
Paramedic's Response to "Burger Flippers" Making an Equal $15/Hour is Beautiful
Craig Carilli9,977 views today ·
The Surprising Nobility of Shit: a Serious Response to President Donald Trump’s ‘Shithole’ Remarks About African Immigrants
Adebayo Akomolafe9,650 views today ·
A Brief History of The 40 Hour Work Week
8 min3,025 views today ·
A Quest for Meaning (2017)
88 min2,136 views today ·
John Lennon's "Imagine," Made Into a Comic Strip
John Lennon. Art by Pablo Stanley1,743 views today ·
Today I Rise: This Beautiful Short Film Is Like a Love Poem For Your Heart and Soul
4 min1,202 views today ·
If MLK Sneezed (MLK's Last Speech)
5 min1,091 views today ·
A Taxonomy of Trump Tweets
George Lakoff757 views today ·
Films for Action — A Social Change-Oriented Alternative to Medium
Films For Action656 views today ·
Load More


Love Films For Action? 

It's hard to rely 100% on ads to keep our organization going.
If you feel like you get some value from this library, consider making a donation today.

Join us on Facebook
Ex-hedge Funder Buys Rights to Life-Saving Drug and Raises Price from $13.50 to $750 per pill